A Phase 2, Randomized, Controlled, Multicenter Study of Vosoritide in Children With Idiopathic Short Stature

What is the goal of the study?

Study 111-210 is a Phase 2, randomized, multicenter study of vosoritide in children with Idiopathic Short Stature (ISS) who are naïve to growth hormone treatment, intended to characterize the short-term efficacy and safety of 3 dosing regimens of vosoritide in reference to placebo in a blinded setting (in the Dose-Finding Phase), and to provide a long-term efficacy and safety assessment of the therapeutic dose of vosoritide versus human growth hormone (hGH) in an open-label setting (in the Long-Term Phase).

Who can participate in the study?

Please contact the study team listed below to learn more.

Study Team:

• PI (Study Doctor): Patricia Fechner
• Study Team Member: Tiffany Hawkins, [email protected]